Evidence map›Paper›PMID 20414335›Full record

ArticleJournal of biomedicine & biotechnology2010

Epo is relevant neither for microvascular formation nor for the new formation and maintenance of mice skeletal muscle fibres in both normoxia and hypoxia.

Luciana Hagström, Onnik Agbulut, Raja El-Hasnaoui-Saadani, Dominique Marchant, Fabrice Favret, Jean-Paul Richalet, Michèle Beaudry, Thierry Launay

Open access · hybridAbstract read
In one paragraph

Article in Journal of biomedicine & biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Insights from the use of erythropoietin in experimental Chagas disease.International journal for parasitology. Drugs and drug resistance · 2022
    Article
  2. Article
  3. Review
  4. Disruption of Angiogenesis by Anthocyanin-Rich Extracts ofInternational journal of scientific and engineering research · 2017
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Endogenous erythropoietin signaling facilitates skeletal muscle repair and recovery following pharmacologically induced damage.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2012
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Luciana HagströmLaboratoire Réponses Cellulaires et Fonctionnelles à l'Hypoxie, Université Paris 13, EA 2363, 97017 Bobigny, France.
Onnik Agbulut
Raja El-Hasnaoui-Saadani
Dominique Marchant
Fabrice Favret
Jean-Paul Richalet
Michèle Beaudry
Thierry Launay
Université Sorbonne Paris Nord · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erythropoietin (Epo) and vascular growth factor (VEGF) are known to be involved in the regulation of cellular activity when oxygen transport is reduced as in anaemia or hypoxic conditions. Because it has been suggested that Epo could play a role in skeletal muscle development, regeneration, and angiogenesis, we aimed to assess Epo deficiency in both normoxia and hypoxia by using an Epo-deficient transgenic mouse model (Epo-TAg(h)). Histoimmunology, ELISA and real time RT-PCR did not show any muscle fiber atrophy or accumulation of active HIF-1alpha but an improvement of microvessel network and an upregulation of VEGFR2 mRNA in Epo-deficient gastrocnemius compared with Wild-Type one. In hypoxia, both models exhibit an upregulation of VEGF120 and VEGFR2 mRNA but no accumulation of Epo protein. EpoR mRNA is not up-regulated in both Epo-deficient and hypoxic gastrocnemius. These results suggest that muscle deconditioning observed in patients suffering from renal failure is not due to Epo deficiency.

Indexed as

Analysis of VarianceAnimalsErythropoietinHistocytochemistryHypoxiaHypoxia-Inducible Factor 1MaleMiceMice, TransgenicMicrovesselsMuscle Fibers, SkeletalMuscle, SkeletalMuscular AtrophyNeovascularization, PhysiologicReceptors, ErythropoietinSarcomeresErythropoietinHypoxia-Inducible Factor 1Receptors, ErythropoietinVascular Endothelial Growth Factors

Identifiers

PMID20414335
PMCPMC2855079
OpenAlexW2005334673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.